Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Acute radiation syndrome (ARS) is a set of conditions that occur in humans following brief exposure to ionizing radiation at doses exceeding 0.7–1.0 Gy. The stages of ARS are as follows:

1.       Prodromal Phase: Begins within hours of exposure and can last up to 2 days.

2.       Latent Phase: A transitional period during which the patient shows no symptoms, lasting up to three weeks but shorter with higher radiation doses.

3.       Illness Phase: Characterized by clinical symptoms such as infection, bleeding, diarrhea, electrolyte imbalances, altered mental state, and shock.

4.       Death or Recovery Phase: Typically unfolds over weeks or months.

There are specific forms of ARS, depending on radiation exposure:

·       Bone marrow syndrome (0.7 to 10.0 Gy)

·       Gastrointestinal syndrome (above 8.0 Gy)

·       Cardiovascular syndrome (above 20.0 Gy)

·       Central nervous system syndrome (above 80.0 Gy)

·       Cutaneous (skin) syndrome (above 10.0 Gy)

As per Thelansis’ research, which encompasses both the secondary and primary research findings, the prevalence of ARS varies between 1.3 to 8.4 /1,000,000 in different countries.

 

Thelansis’s “Acute Radiation Syndrome (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Radiation Syndrome (ARS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Acute Radiation Syndrome (ARS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acute Radiation Syndrome (ARS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Acute Radiation Syndrome (ARS), Acute Radiation Syndrome (ARS) market outlook, Acute Radiation Syndrome (ARS) competitive landscape, Acute Radiation Syndrome (ARS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)